Larvol Delta - ACELYRIN-INC-Announces-Positive-16week-Data-From-its-Global-Phase-2b3-Trial-of-Izokibep-in-Psoriatic-Arthritis-to-be-Shared-During-LateBreaking-Oral-Presentation-at-EULAR-2024

izokibep (ABY-035) - ACELYRIN

https://www.globenewswire.com/news-release/2024/06/05/2893738/0/en/ACELYRIN-INC-Announces-Positive-16-week-Data-From-its-Global-Phase-2b-3-Trial-of-Izokibep-in-Psoriatic-Arthritis-to-be-Shared-During-Late-Breaking-Oral-Presentation-at-EULAR-2024.html

Jun 5, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next